915967-82-7
中文名稱
4,4'-(1,3-丙烷雙-4,1-哌嗪基)雙(7-氯喹啉)磷酸鹽水合物
英文名稱
4,4'-(1,3-Propanediyldi-4,1-piperazinediyl)bis(7-chloroquinoline) phosphate hydrate
CAS
915967-82-7
分子式
C29H32Cl2N6.4(H3PO4).4(H2O)
分子量
651.521
MOL 文件
915967-82-7.mol
更新日期
2023/03/20 19:41:17
915967-82-7 結(jié)構(gòu)式
基本信息
中文別名
四磷酸哌喹磷酸哌喹四水物
化合物T7744
四磷酸哌喹四水合物
4,4'-(1,3-丙烷雙-4,1-哌嗪基)雙(7-氯喹啉)磷酸鹽水合物
1,3-二[4-(7-氯-4-喹啉基)-1-哌嗪基]丙烷 四磷酸鹽四水合物
英文別名
Piperaquine tetraphosphate tetrahydrate1,3-Bis[4-(7-chloroquinolin-4-yl)piperazin-1-yl]propane Tetraphosphate
1,3-Bis[4-(7-chloro-4-quinolinyl)-1-piperazinyl]propane tetraphosphate tetrahydrate
4,4'-(1,3-Propanediyldi-4,1-piperazinediyl)bis(7-chloroquinoline) phosphate hydrate
所屬類別
醫(yī)藥中間體：哌嗪類化合物安全數(shù)據(jù)
警示詞警告
危險(xiǎn)性描述H315-H319-H335
危險(xiǎn)品標(biāo)志Xi
危險(xiǎn)類別碼36/37/38
安全說明26
WGK Germany3
海關(guān)編碼2933.59.8000
4,4'-(1,3-丙烷雙-4,1-哌嗪基)雙(7-氯喹啉)磷酸鹽水合物價(jià)格(試劑級)
| 報(bào)價(jià)日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價(jià)格 |
| 2024/11/08 | HY-B1896B | 4,4'-(1,3-丙烷雙-4,1-哌嗪基)雙(7-氯喹啉)磷酸鹽水合物 Piperaquine tetraphosphate tetrahydrate | 915967-82-7 | 5mg | 200元 |
| 2024/11/08 | HY-B1896B | 4,4'-(1,3-丙烷雙-4,1-哌嗪基)雙(7-氯喹啉)磷酸鹽水合物 Piperaquine tetraphosphate tetrahydrate | 915967-82-7 | 10mg | 320元 |
| 2024/11/08 | HY-B1896B | 4,4'-(1,3-丙烷雙-4,1-哌嗪基)雙(7-氯喹啉)磷酸鹽水合物 Piperaquine tetraphosphate tetrahydrate | 915967-82-7 | 25mg | 640元 |
常見問題列表
生物活性
Piperaquine tetraphosphate tetrahydrate 是一種雙喹啉抗瘧藥，可以與青蒿素聯(lián)用于抗瘧研究。體內(nèi)研究
Piperaquine (10-90 mg/kg; a single i.p.) decreases parasitemia at all of the doses tested in mice.
Piperaquine (90 mg/kg; a single i.p.) exhibits the t
1/2
, apparent clearance, and apparent volume of distribution 17.8 days, 33.5 mg?h/L, 1.55 L/h/kg, and 956 L/kg, respectively, in healthy mice and 16.1 days, 27.3 mg?h/L, 1.9 L/h/kg, and 1,059 L/kg in malaria-infected mice.
| Animal Model: | Male BALB/c mice (7 to 8 weeks) are inoculated with Plasmodium berghei parasites |
| Dosage: | 0, 10, 30, 90 mg/kg |
| Administration: | A single i.p. administration |
| Result: |
The median survival time was 10 days at dose of 10 mg/kg.
The median survival time was 54 days at dose of 30 mg/kg. All mice were active and alert and had stable body weights throughout the course of the study at dose of 90 mg/kg. |
| Animal Model: | Male Swiss mice (6 weeks old) |
| Dosage: | 90 mg/kg (Pharmacokinetic Analysis) |
| Administration: | A single i.p. administration |
| Result: | t 1/2 =17.8 d; AUC=33.5 mg?h/L; apparent clearance=1.55 L/h/kg; apparent volume of distribution=956 L/kg. |